Close

Aptars Activ Blister Packaging Solution Approved by U.S. FDA for Oral Solid Dose HIV Prevention Medicine

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Future of Drug Packaging: Safety, Sustainability, Innovation

The development of medication packaging stands out as a...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Aptar announced that its Activ-Blister packaging solution for oral solid dose drug delivery was recently approved by the U.S. FDA for a HIV prevention medicine.

The oral solid dose drug was developed by a leading pharmaceutical company in the HIV treatment and prevention space, and represents the first FDA approval of Aptar’s proprietary Activ-Blister™ packaging solution and proprietary application process developed by Aptar CSP Technologies.

The system protects oral solid drug products with a 3-Phase Activ-Polymer™ solution that is fully integrated into the blister package. This 3-Phase Activ-Polymer™ technology, which can be customized specifically for the drug developer’s formulation, offers a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.

Aptar’s portfolio of 3-Phase Activ-Polymer™ protective solutions helps biotech and pharmaceutical partners meet specific drug long-term and in-use stability requirements while maintaining therapeutic efficacy, all in a patient-friendly packaging configuration.

“I am very pleased to announce this recent FDA approval of our proprietary Activ-Blister™ technology,” commented Stephan Tanda, Aptar’s President and CEO. “This is a significant step that further validates the expanding portfolio of solutions offered by Aptar CSP Technologies. We will continue to leverage our proprietary 3-Phase Activ-Polymer™ technology to help our customers with unique protective formulations that derisk their drug development process and help strengthen their own offerings. The ultimate result is that we are creating meaningful solutions that help improve and save lives.”

Latest stories

Related stories

API China 2025 Concludes with Strong Turnout and Industry-Wide Momentum

Asia’s leading pharma show draws 200,000 visits and nearly...

Recyclable Pharma Packaging: Market To Hit $335B By 2032

There will be a lot more demand for recyclable...

Future of Drug Packaging: Safety, Sustainability, Innovation

The development of medication packaging stands out as a...

Key Trends Shaping Indian Pharmaceutical Packaging Market

The pharmaceutical business has a major economic influence on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back